Diese Analysten bewerten die MorphoSys-Aktie
Analyst | Kursziel | Abstand Kursziel | Datum | |
---|---|---|---|---|
UBS AG | 68,00 EUR | - | 06.05.2024 | |
JP Morgan Chase & Co. | 31,00 EUR | - | 06.02.2024 | |
Deutsche Bank AG | 25,00 EUR | - | 31.01.2024 |
Werbung
Kursziele im Branchenvergleich
Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
---|---|---|---|---|---|
Agennix AG | 0 | 0 | 0 | - | - |
Amgen Inc. | 0 | 0 | 0 | - | - |
Bayer | 1 | 8 | 0 | 24,12 EUR | +14,20% |
BB Biotech AG | 0 | 0 | 0 | - | - |
Biogen Inc | 0 | 0 | 0 | - | - |
Biotest AG | 0 | 0 | 0 | - | - |
Eli Lilly | 1 | 0 | 0 | 994,00 USD | +36,97% |
EVOTEC SE | 2 | 2 | 1 | 9,68 EUR | +20,70% |
Johnson & Johnson | 0 | 0 | 0 | - | - |
MorphoSys | 1 | 2 | 0 | 41,33 EUR | - |
Novartis AG | 3 | 5 | 1 | 98,86 CHF | +10,68% |
Pfizer Inc. | 3 | 3 | 0 | 31,20 USD | +18,63% |
QIAGEN N.V. | 5 | 2 | 0 | 48,45 EUR | +8,15% |
Roche Holding AG (Inhaberaktie) | 0 | 0 | 0 | - | - |
Sanofi S.A. | 5 | 2 | 1 | 109,86 EUR | +11,69% |